“Dental professionals will soon have a new and valuable
tool that will help their patients avoid cavities. We are
now evaluating commercialization strategies and are
pursuing US FDA and worldwide marketing clearances.”
US patent 9,277,875, “Device for the Detection of Non-Cavitated Early Dental Caries Lesions,” was issued to the
Research Foundation for the State University of New York
(Albany, New York). Te technology was developed at
Stony Brook University School of Dental Medicine.
Ortek has exclusive worldwide licensing rights to this
patented technology. Patents covering this device have
also been issued in Australia, China, and Mexico, with
other patents pending worldwide.
Trough a strategic alliance with the Research
Foundation of State University of New York, Ortek has
developed major scientifc breakthroughs in oral and
cutaneous microbiome technology. Te company has
developed and commercialized revolutionary technology
for dental cavity prevention, detection, and treatments for
dentinal sensitivity. Te company’s core oral microbiome
AlkaGen technology, which is contained in its proprietary
BasicBites soft-chew confections, is based on the scientifc
expertise of researchers in the Department of Oral Biology
and Pathology at Stony Brook University School of Dental
Medicine. —Ortek Terapeutics Inc. press release 16 March 2016
STRAUMANN AND ANTHOGYR
Anthogyr opens door for Straumann to enter fast-growing
value segment in China
Straumann (Basel, Switzerland) and dental implant manufacturer Anthogyr (Sallanches, France) have announced a
partnership agreement that enables the Swiss company to
invest in Anthogyr and to address a broader section of the
fast-growing tooth replacement market in China.
Anthogyr’s dental implant system is registered and
established in China where it is positioned as a high-
quality, attractively priced option. Te agreement
foresees the transfer of Anthogyr’s implantology business
activities in China to Straumann by midyear, giving the
latter access to the fast-growing value segment there.
Te combination of the two companies’ sales capabilities
is expected to provide the critical mass to compete and
grow successfully in this segment. Straumann already
leads the premium segment in China and has recently
Te FDA has determined that the banning standard
would not apply to powdered radiographic protection
gloves. Te agency is not aware of any powdered
radiographic protection gloves that are currently on the
market. Nonpowdered surgeon gloves and nonpowdered
patient examination gloves will also not be included
in the ban and will remain Class I medical devices.
Terefore, the FDA is also proposing amendments to its
classifcation regulations to clarify that they apply only to
Te proposed rule is available online for public
comment for 90 days at regulations.gov.—FDA press release 21
WITH HELP OF STONY BROOK
UNIVERSITY, ORTEK AWARDED PATENT
FOR PRECAVITY DETECTION DEVICE
New device relies on electrical properties of demineralized
In April, Ortek Terapeutics Inc. (Roslyn Heights, New
York) announced that it had been awarded a patent for
the Ortek ECD dental device, a system for detecting early
or precavity lesions that cannot be readily detected by
visual examination or x-ray.
Human and laboratory clinical studies have demonstrated that the ECD device can detect the earliest stages
of tooth demineralization or precavity lesions with 100%
Te ECD device is designed to detect precavity lesions
in molars and premolars. Te biting surfaces of these
teeth have deep grooves that often retain acid-producing
bacteria. Over time, acid attacks can lead to tooth mineral loss, which initiates the development of cavities.
Tooth enamel is electrically non-conductive unless
breached by demineralization or fracture. When this
occurs, dentinal fuid percolates through the breached
enamel site and enables the battery-powered ECD to
complete its electrical circuit.
Te ECD device features a handpiece with a probe tip
and can precisely measure the amount of dentinal fuid
seepage. Te more fuid it detects, the greater the extent
of the precavity lesion. Tis data enables the dental
practitioner to determine the severity of any lesions and
design an appropriate treatment plan that could include
minimally invasive care.
“We believe the ECD is a major breakthrough in
oral care,” says Mitchell Goldberg, president of Ortek.